Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:20:42.808Z.
Consensus retrieved: 2026-10-06T08:50:40.583Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:20:42.808Z.
Quote observation: 2026-10-06T19:20:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 236ecad6846b0cc00793ea2ceb9f38c60eee5e96b58175726d9ae7432cdeb63e
Forward PE Ratio (N/A) = Dated Quote Price ($4.08) / Consensus Forward EPS ($-1.05)
FORWARD PE RATIO
N/A
Annexon, Inc.
Market Cap
$667.66M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Annexon, Inc. (ANNX) | $667.66M | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $663.33M | N/A |
| Helus Pharma Inc. (HELP)vs › | $662.06M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $659.74M | N/A |
| Starling Oncology, Inc. (STLN)vs › | $657.39M | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $680.78M | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $680.93M | N/A |
| Prime Medicine, Inc. (PRME)vs › | $655.68M | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $690.22M | N/A |
| Verastem, Inc. (VSTM)vs › | $690.25M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.08, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.05 | $-1.10 – $-0.99 | 6 | n/m |
| 2027-12-31 | $-1.00 | $-1.15 – $-0.82 | 6 | n/m |
| 2028-12-31 | $-0.24 | $-1.85 – $2.37 | 8 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
